Clinical trial
Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune…
NCT00486421 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00486421 |
|---|---|
| Title | Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura |
| Official title | A Pilot Study of Rituximab in Combination With Corticosteroids for the Initial Treatment of Immune Thrombocytopenic Purpura |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Early Phase 1 |
| Study type | Interventional |
| Conditions | Nonneoplastic Condition |
| Intervention type | Biological, Drug |
| Interventions | Rituximab, Prednisone |
| Enrollment | 22 |
| Start date | Jan 1, 2007 |
| Primary completion | May 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Jun 14, 2007 |
| Last update posted | Oct 17, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: